GoAI
Get started
ImmuCell Corporation logo

ImmuCell Corporation

ICCC

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$10.13

−$0.03 · -0.30%

Aug 21, 3:55 PM ET

ICCC company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

64

Undervalued

Momentum

77

Gaining

Sentiment

64

Bullish

Risk resilience

54

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
F. Olivier Te Boekhorst
Listed since
May 5, 1987
Employees
73

Market position

Volume
11.13K
0.37× average
Average volume
30.14K
Average daily volume
Market cap
91.01M USD
Beta
0.57
Market reference 1

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
118.91×
P/B (TTM)
2.91×
P/S (TTM)
2.97×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
40.32%
Operating margin
12.60%
Net margin
2.57%

Financial health

Debt / equity
0.4×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends53%22%-10%-41%Gross margin, FY2021: 44.98%Gross margin, FY2022: 41.19%Gross margin, FY2023: 25.16%Gross margin, FY2024: 29.97%Gross margin, FY2025: 41.40%Operating margin, FY2021: 1.34%Operating margin, FY2022: -12.38%Operating margin, FY2023: -32.90%Operating margin, FY2024: -6.19%Operating margin, FY2025: 5.97%Net margin, FY2021: -0.41%Net margin, FY2022: -13.43%Net margin, FY2023: -33.05%Net margin, FY2024: -8.14%Net margin, FY2025: -3.76%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 44.98%. Gross margin FY2022 41.19%. Gross margin FY2023 25.16%. Gross margin FY2024 29.97%. Gross margin FY2025 41.40%. Operating margin FY2021 1.34%. Operating margin FY2022 -12.38%. Operating margin FY2023 -32.90%. Operating margin FY2024 -6.19%. Operating margin FY2025 5.97%. Net margin FY2021 -0.41%. Net margin FY2022 -13.43%. Net margin FY2023 -33.05%. Net margin FY2024 -8.14%. Net margin FY2025 -3.76%.

Income trends

Revenue

27.64M USD+4.34%

Operating income

1.65M USD+3.29M USD

Net income

−1.04M USD+51.78%
Income trends across reported periods30.99M USD17.62M USD4.25M USD−9.12M USDRevenue, FY2021: 19.24M USDRevenue, FY2022: 18.57M USDRevenue, FY2023: 17.47M USDRevenue, FY2024: 26.49M USDRevenue, FY2025: 27.64M USDOperating income, FY2021: 257.39K USDOperating income, FY2022: −2.3M USDOperating income, FY2023: −5.75M USDOperating income, FY2024: −1.64M USDOperating income, FY2025: 1.65M USDNet income, FY2021: −78.29K USDNet income, FY2022: −2.49M USDNet income, FY2023: −5.77M USDNet income, FY2024: −2.16M USDNet income, FY2025: −1.04M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 19.24M USD. Revenue FY2022 18.57M USD. Revenue FY2023 17.47M USD. Revenue FY2024 26.49M USD. Revenue FY2025 27.64M USD. Operating income FY2021 257.39K USD. Operating income FY2022 −2.3M USD. Operating income FY2023 −5.75M USD. Operating income FY2024 −1.64M USD. Operating income FY2025 1.65M USD. Net income FY2021 −78.29K USD. Net income FY2022 −2.49M USD. Net income FY2023 −5.77M USD. Net income FY2024 −2.16M USD. Net income FY2025 −1.04M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue27.64M USD26.49M USD17.47M USD18.57M USD19.24M USD
Cost of goods sold16.2M USD18.55M USD13.08M USD10.92M USD10.59M USD
Gross profit11.45M USD7.94M USD4.4M USD7.65M USD8.66M USD
Research and development3.04M USD3.9M USD4.39M USD4.49M USD4.17M USD
Selling, general, and administrative6.75M USD5.68M USD5.22M USD5.45M USD4.23M USD
Operating expenses9.8M USD9.58M USD10.14M USD9.95M USD8.4M USD
Interest income158.71K USD77.7K USD96.57K USD153.1K USD18.81K USD
Interest expense439.04K USD568.73K USD452.98K USD348.54K USD314.36K USD
Depreciation and amortization2.73M USD2.69M USD2.72M USD2.49M USD2.46M USD
Operating income1.65M USD−1.64M USD−5.75M USD−2.3M USD257.39K USD
Net income−1.04M USD−2.16M USD−5.77M USD−2.49M USD−78.29K USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
67%
2 beats, 1 miss, 0 met estimates
Average EPS surprise
-793.33%
3 comparable reports
Latest EPS result
0.2
Estimate 0.05 · Beat by 300.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates0.250.05-0.15-0.35Q1 '25No estimateQ2 '25No estimateQ3 '25No estimateQ4 '25No estimateQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 25, 2025: actual 0.06, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 14, 2025: actual 0.16, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 14, 2025: actual 0.06, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 13, 2025: actual -0.02, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 4, 2026: actual -0.31, estimate -0.01, surprise -3000.00%, Miss. Q2 2026, reported May 14, 2026: actual 0.21, estimate 0.05, surprise +320.00%, Beat. Q3 2026, reported Aug 13, 2026: actual 0.2, estimate 0.05, surprise +300.00%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate 0.05, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates10.77M8.84M6.91M4.99MQ1 '25No estimateQ2 '25No estimateQ3 '25No estimateQ4 '25No estimateQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 25, 2025: actual 7.75M USD, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 14, 2025: actual 8.07M USD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 14, 2025: actual 6.44M USD, estimate —, surprise —, Comparison unavailable. Q4 2025, reported Nov 13, 2025: actual 5.51M USD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 4, 2026: actual 7.63M USD, estimate 5.4M USD, surprise +41.22%, Beat. Q2 2026, reported May 14, 2026: actual 10.36M USD, estimate 5.4M USD, surprise +91.77%, Beat. Q3 2026, reported Aug 13, 2026: actual 7.19M USD, estimate 5.4M USD, surprise +33.05%, Beat. Q4 2026, reported Nov 12, 2026: actual —, estimate 5.4M USD, surprise —, Comparison unavailable.

Corporate actions

Corporate action history

Stock split

Effective Jul 25, 1990

1:100

ICCC peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research ICCC

research.disclaimer